58m
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback